Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1972 2
1973 1
1974 1
1975 1
1976 1
1977 2
1978 1
1980 3
1981 3
1982 4
1983 4
1984 2
1985 4
1986 2
1987 2
1988 1
1990 1
1993 2
1994 6
1996 2
1997 3
1998 5
1999 6
2000 6
2002 1
2003 3
2004 4
2005 4
2006 3
2007 2
2008 9
2009 1
2010 3
2011 6
2012 9
2013 4
2014 6
2015 3
2016 9
2017 12
2018 13
2019 6
2020 6
2021 8
2022 15
2023 14
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

193 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for had a wasfi
Your search for Hadya Waqfi retrieved no results
Clinical phenotyping in sarcoidosis using cluster analysis.
Lin NW, Arbet J, Mroz MM, Liao SY, Restrepo CI, Mayer AS, Li L, Barkes BQ, Schrock S, Hamzeh N, Fingerlin TE, Carlson NE, Maier LA. Lin NW, et al. Respir Res. 2022 Apr 9;23(1):88. doi: 10.1186/s12931-022-01993-z. Respir Res. 2022. PMID: 35397561 Free PMC article.
Clusters 4, 5, 6 were significantly more likely to have ever been on immunosuppressive treatment and had higher Wasfi disease severity scores. CONCLUSIONS: Cluster analysis produced 6 sarcoidosis phenotypes that demonstrated less severe and severe phenotypes. Phenotypes 1, …
Clusters 4, 5, 6 were significantly more likely to have ever been on immunosuppressive treatment and had higher Wasfi disease severit …
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.
Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, Li S, Kimball AB. Blauvelt A, et al. J Am Acad Dermatol. 2017 Mar;76(3):405-417. doi: 10.1016/j.jaad.2016.11.041. Epub 2017 Jan 2. J Am Acad Dermatol. 2017. PMID: 28057360 Free article. Clinical Trial.
The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance.
Tegally H, San JE, Cotten M, Moir M, Tegomoh B, Mboowa G, Martin DP, Baxter C, Lambisia AW, Diallo A, Amoako DG, Diagne MM, Sisay A, Zekri AN, Gueye AS, Sangare AK, Ouedraogo AS, Sow A, Musa AO, Sesay AK, Abias AG, Elzagheid AI, Lagare A, Kemi AS, Abar AE, Johnson AA, Fowotade A, Oluwapelumi AO, Amuri AA, Juru A, Kandeil A, Mostafa A, Rebai A, Sayed A, Kazeem A, Balde A, Christoffels A, Trotter AJ, Campbell A, Keita AK, Kone A, Bouzid A, Souissi A, Agweyu A, Naguib A, Gutierrez AV, Nkeshimana A, Page AJ, Yadouleton A, Vinze A, Happi AN, Chouikha A, Iranzadeh A, Maharaj A, Batchi-Bouyou AL, Ismail A, Sylverken AA, Goba A, Femi A, Sijuwola AE, Marycelin B, Salako BL, Oderinde BS, Bolajoko B, Diarra B, Herring BL, Tsofa B, Lekana-Douki B, Mvula B, Njanpop-Lafourcade BM, Marondera BT, Khaireh BA, Kouriba B, Adu B, Pool B, McInnis B, Brook C, Williamson C, Nduwimana C, Anscombe C, Pratt CB, Scheepers C, Akoua-Koffi CG, Agoti CN, Mapanguy CM, Loucoubar C, Onwuamah CK, Ihekweazu C, Malaka CN, Peyrefitte C, Grace C, Omoruyi CE, Rafaï CD, Morang'a CM, Erameh C, Lule DB, Bridges DJ, Mukadi-Bamuleka D, Park D, Rasmussen DA, Baker D, Nokes DJ, Ssemwanga D, Tshiabuila D, Amuzu DSY, Goedhals D,… See abstract for full author list ➔ Tegally H, et al. Science. 2022 Oct 7;378(6615):eabq5358. doi: 10.1126/science.abq5358. Epub 2022 Oct 7. Science. 2022. PMID: 36108049 Free PMC article.
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK, Gordon KB. Reich K, et al. J Am Acad Dermatol. 2017 Mar;76(3):418-431. doi: 10.1016/j.jaad.2016.11.042. Epub 2017 Jan 2. J Am Acad Dermatol. 2017. PMID: 28057361 Free article. Clinical Trial.
Pulmonary Sarcoidosis and Immune Dysregulation: A Pilot Study on Possible Correlation.
Cifaldi R, Salton F, Confalonieri P, Trotta L, Barbieri M, Ruggero L, Valeri G, Pozzan R, Della Porta R, Kodric M, Baratella E, Bellan M, Lerda S, Hughes M, Confalonieri M, Cova MA, Gandin I, Mondini L, Ruaro B. Cifaldi R, et al. Diagnostics (Basel). 2023 Sep 11;13(18):2899. doi: 10.3390/diagnostics13182899. Diagnostics (Basel). 2023. PMID: 37761266 Free PMC article.
OBJECTIVE: The aim of this study was to evaluate whether immune system alterations detected by lymphocyte typing in peripheral blood correlate with the severity of sarcoidosis, calculated according to two separate severity scores proposed by Wasfi in 2006 and Hamzeh in 201 …
OBJECTIVE: The aim of this study was to evaluate whether immune system alterations detected by lymphocyte typing in peripheral blood correla …
Interferon-inducible chemokines reflect severity and progression in sarcoidosis.
Su R, Nguyen ML, Agarwal MR, Kirby C, Nguyen CP, Ramstein J, Darnell EP, Gomez AD, Ho M, Woodruff PG, Koth LL. Su R, et al. Respir Res. 2013 Nov 7;14(1):121. doi: 10.1186/1465-9921-14-121. Respir Res. 2013. PMID: 24199653 Free PMC article.
Comparisons were made between groups and clinical course using pulmonary function measures and a severity score developed by Wasfi et al. RESULTS: In a cross-sectional analysis of 36 non-immunosuppressed sarcoidosis subjects, serum CXCL9, CXCL10, and sIL2R were significant …
Comparisons were made between groups and clinical course using pulmonary function measures and a severity score developed by Wasfi et …
193 results